65 Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis.

64 Targeting of p53- and PUMA-dependent apoptosis protects intestinal stem cells, but not cancer cells, against chemotherapy.

63 Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism.

62 Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.

61 Elevated d-2-hydroxyglutarate during colitis drives progression to colorectal cancer.

60 Precision editing of the gut microbiota ameliorates colitis.

59 Commensal Fungi Recapitulate the Protective Benefits of Intestinal Bacteria.

58 Recurrent infection progressively disables host protection against intestinal inflammation.

57 Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

56 Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Free Images for Presentation: sunipix SUNIPIX